Return to homepagePandemic Pact

Development, characterization and evaluation of protective efficacy of self amplifying mRNA vaccine candidates against the Severe acute respiratory syndrome coronavirus 2 (SARS CoV2)

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    N/A

  • Funder

    BIRAC

  • Principal Investigator

    Milan Surjit

  • Research Location

    India

  • Lead Research Institution

    Translational Health Science and Technology Institute (THSTI)

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Clinical trial (unspecified trial phase)

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Propose to evaluate the efficacy of self-amplifying mRNA SAM technology to develop a potent vaccine against the SARSCoV-2. Our approach involves production of vaccine antigen inside the host by delivering a self-amplifying mRNA that encodes the antigen of interest. S protein of SARS-CoV-2 is being used as the vaccine antigen.